**CLAIMS**

1. Use of a wafer solid dosage form in the manufacture of a medicament for treating major depressive disorder or treatment-resistant depression, wherein said dosage form comprises:

   (a) ketamine or a salt form thereof at a dose of about 25 mg to about 150 mg;
   (b) about 2 to about 20% w/w amorphous, non-ionic matrix forming agent; and
   (c) about 40% to about 80% w/w crystalline matrix forming agent;

   wherein the dosage form dissolves in an oral cavity; wherein said dosage form disintegrates in the oral cavity in a time of less than 15 seconds and dissolves in the oral cavity in a time of less than 60 seconds, and wherein ketamine is detected in vivo within 5 minutes; and wherein said dosage form is to be administered sublingually to a patient in need thereof.

2. The use according to claim 1, wherein the wafer is freeze-dried.

3. The use according to claim 1, wherein the solid dosage form is fast disintegrating.

4. The use according to claim 1, wherein the biologically active material is absorbed by diffusion directly into the systemic circulation.

5. The use according to claim 1, wherein the biologically active material is ketamine.

6. The use according to claim 5, wherein the ketamine is present in an amorphous (non-crystalline) state.

7. The use according to claim 1, wherein the amorphous, non-ionic matrix forming agent comprises amylopectin.

8. The use according to claim 7, wherein the amylopectin is not in the form of a starch or modified starch.

9. The use according to claim 1, wherein the crystalline matrix forming agent comprises a carbohydrate.

10. The use according to claim 1 wherein the powder x-ray diffraction (XRD) spectrum of the dosage form comprises peaks at 2-theta values at approximately 9.58 degrees, 19.68 degrees, and 20.05 degrees.

11. The use according to claim 1, wherein the solid dosage form is porous.

12. The use according to claim 1, wherein the solid dosage form comprises a dose of ketamine selected from the group consisting of: 25mg, 50mg, 75mg, 100mg, 150mg.

13. The use according to claim 1, wherein the solid dosage form provides an effective plasma concentration of ketamine material within a period of no more than two hours, 30 minutes, 20 minutes, or 15 minutes.

14. The use according to claim 1 wherein the solid dosage form provides a $C_{max}$ of 10 $ng/ml^{-1}$ and 200 $ng/ml^{-1}$.

15. The use according to claim 1, wherein the solid dosage form provides a $t_{max}$ between 10 mins and 1 hour.

16. The use according to claim 6, wherein the ketamine is rapidly absorbed with detectable concentrations at a first sampling time of 3 minutes.

17. The use according to claim 1, wherein the dosage form is administered to the subject utilising a dosing regimen selected from the group consisting of: at a frequency to alleviate the symptoms of depression, twice hourly, once every six hours, once every 12 hours, once daily, twice weekly, once weekly, once every two weeks, once a month, every two months, once every six months, once yearly.

18. Use of a fast dissolving wafer solid dosage form in the manufacture of a medicament for improving uptake of ketamine in a patient suffering from major depressive disorder or treatment-resistant depression, wherein said dosage form comprises:

    (a) ketamine or a salt form thereof at a dose of about 25 mg to about 150 mg; and

    (b) about 2 to about 20% w/w amorphous matrix forming agent; and

    (c) about 40% to about 80% w/w crystalline matrix forming agent;

    wherein the dosage form dissolves in an oral cavity without leaving a residue of said dosage form; and wherein said dosage form disintegrates in the oral cavity in a time of less than 15 seconds and dissolves in the oral cavity in a time of less than 60 seconds; and wherein ketamine is detected in vivo within 5 minutes; and wherein said dosage form is to be administered sublingually to the patient in need thereof.

19. Use of a wafer solid dosage form in the manufacture of a medicament for treating depression-related suicidal ideation, wherein said dosage form comprises:

    (a) ketamine or a salt form thereof at a dose of about 25 mg to about 150 mg;

    (b) about 2 to about 20% w/w amorphous, non-ionic matrix forming agent; and

    (c) about 40% to about 80% w/w crystalline matrix forming agent;

    wherein the dosage form dissolves in an oral cavity; and wherein said dosage form disintegrates in the oral cavity in a time of less than 15 seconds and dissolves in the oral cavity in a time of less than 60 seconds, and wherein ketamine is detected in vivo within 5 minutes; and wherein said dosage form is to be administered sublingually to a patient in need thereof.

20. Use of a fast dissolving wafer solid dosage form in the manufacture of a medicament for improving uptake of ketamine in a patient suffering from suicidal ideation and/or drug-resistant depression,

    wherein the dosage form comprises:

    (a)ketamine or a salt form thereof at a dose of about 25 mg to about 150 mg; and

    (b)about 2 to about 20% w/w amorphous matrix forming agent; and

    (c) about 40% to about 80% w/w crystalline matrix forming agent;

    wherein the dosage form dissolves in an oral cavity without leaving a residue of said dosage form;

    wherein the dosage form disintegrates in the oral cavity in a time of less than 15 seconds and dissolves in the oral cavity in a time of less than 60 seconds;

    wherein the ketamine is detected in vivo within 5 minutes;

    wherein the ketamine is rapidly absorbed with detectable concentrations at a first sampling time of 3 minutes; and

wherein said dosage form is to be administered sublingually to the patient in need thereof and the rapid therapeutic action of the ketamine is caused by a detectable blood ketamine concentration within minutes of sublingual administration;

wherein the rapid therapeutic action of the ketamine results in action in the brain;

wherein the first exposure effect causes at least one of the following effects: glutamate modulation; synaptic repair; inflammation reduction; and network resetting.